Back to News
Market Impact: 0.18
Barclays Initiates Coverage of Ligand Pharmaceuticals Incorporated - Equity Right at Overweight
Source: Nasdaq
Analyst InsightsHealthcare & Biotech
Barclays initiated coverage of Ligand Pharmaceuticals Incorporated Equity Right (OTCPK: LGNXZ) on September 25, 2026, with an Overweight recommendation. The positive analyst action may support sentiment toward the biotech-linked security, though the article provides no price target, financial estimates, or operating updates.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
BCS0.10
LGND0.55
More News
- Humana surges: Barclays bets big on Medicare star ratings rebound
- Top Wall Street Forecasters Revamp Levi Strauss Expectations Ahead Of Q3 Earnings
- PepsiCo Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
- Shares of Akamai surge after deal with Anthropic. What Wall Street is saying
- Wall Street Week | China’s Trade Reckoning, Syracuse’s Second Chance, Humanoids in Healthcare
- Yields keep rising, Novo's tough week, why cat product sales are surging and more in Morning Squawk